Go Back to Previous Page »

Xarelto Mass Tort Litigation

Xarelto (rivaroxaban) is one of a new class of anticoagulants (blood thinners) called direct factor Xa inhibitors.  Xarelto is prescribed for three primary indications:

  • to reduce the risk of blood clots and stroke in patients with atrial fibrillation;
  • to treat deep vein thrombosis and pulmonary embolism;
  • to reduce the risk of blood clots in patients undergoing knee or hip replacement surgery.

Xarelto is manufactured by Janssen Pharmaceuticals, a Johnson & Johnson pharmaceutical company, and Bayer.  Xarelto was FDA approved in November 2011 and is marketed as supporting patient compliance by offering convenient oral dosing, no routine coagulation monitoring, and no known dietary restrictions.

Xarelto has been linked to a large number of injuries requiring hospitalizations with some resulting in deaths. Like all blood thinners, Xarelto can cause serious internal bleeding in some. The most common adverse events were:

  • Gastrointestinal hemorrhage
  • Pulmonary embolism (PE)
  • Deep vein thrombosis (DVT)

Other reported adverse events included:

  • Thrombosis
  • Decrease in hemoglobin
  • Cerebrovascular accidents (CVA or strokes
  • Heart attack (myocardial infarction)
  • Hematoma
  • Thrombotic thrombocytopenic purpura (TTP)
  • Frequent and severe nosebleeds and
  • Blood in the urine or stool.

Xarelto bleeding is difficult to stop, as there is currently no known reversal agent for this occurrence, therefore hemorrhaging will continue until the drug is cleared from the system.

A retrospective analysis of the data was done from patients who had a temporary discontinuation, early permanent study-drug discontinuation, as well as all patients who completed the trial and transitioned to open-label therapy from the ROCKET-AF trial that compared rivaroxaban (Xarelto) with warfarin (Coumadin) for the prevention of stroke in patients with nonvalvular atrial fibrillation, shows that stopping these anticoagulant medications puts patients at high risk for stroke or systemic embolism and other thrombotic events, including MI and death up to 30 days post-discontinuation.

Wexler Wallace Xarelto Lawsuits

Wexler Wallace LLP is providing case evaluations for individuals who may have been injured while taking Xarelto. All consultations are free and completely confidential. Our experienced dangerous pharmaceutical and medical device attorneys have successfully handled many similar cases in the past. If you or someone you know has experienced any of the symptoms listed above as a result of taking Xarelto, you may be eligible to file a suit. Please contact us or complete our Online Form.

Wexler Wallace also welcomes inquiries from other counsel considering referring a case with respect to Xarelto injuries.  We maintain significant relationships with other firms and counsel of the highest quality throughout the United States.